Alzheimer's Disease Apolipoprotein and Lipid Transport Therapy Companies

Overview

This category page covers biotechnology and pharmaceutical companies developing apolipoprotein-targeted therapies, lipid transport modulators, and HDL function enhancers for Alzheimer's disease. The [apolipoprotein E](/genes/apoe) (APOE) gene is the strongest genetic risk factor for late-onset AD, with the APOE4 allele increasing risk 3-4x in heterozygotes and 10-12x in homozygotes. ABCA1 and ABCG1 transporters regulate brain cholesterol and lipid homeostasis, critical for neuronal function, synaptic plasticity, and amyloid clearance.

Overview

This category page covers biotechnology and pharmaceutical companies developing apolipoprotein-targeted therapies, lipid transport modulators, and HDL function enhancers for Alzheimer's disease. The [apolipoprotein E](/genes/apoe) (APOE) gene is the strongest genetic risk factor for late-onset AD, with the APOE4 allele increasing risk 3-4x in heterozygotes and 10-12x in homozygotes. ABCA1 and ABCG1 transporters regulate brain cholesterol and lipid homeostasis, critical for neuronal function, synaptic plasticity, and amyloid clearance.

Companies targeting this pathway aim to restore proper lipid transport, enhance HDL-like particle function in the brain, reduce amyloid burden, and protect against APOE4-associated neurodegeneration.

Key Therapeutic Approaches

| Approach | Description | Companies |
|----------|-------------|-----------|
| APOE4 Function Correctors | Small molecules restoring APOE4 function to APOE3-like | Eli Lilly (LY3372689), AC Immune |
| ABCA1 Modulators | Enhance ABCA1 expression to improve APOE lipidation | Denali, Acer Therapeutics |
| ABCG1 Modulators | Target ABCG1 for cholesterol efflux and neuroprotection | Denali, academia |
| HDL Function Enhancers | Enhance brain HDL-like particle function | Lexeo Therapeutics, Cerenis |
| APOE Gene Therapy | Deliver APOE2 or APOE3 via AAV for APOE4 carriers | Lexeo Therapeutics |
| LDL Receptor Modulators | Target LDL receptor family for brain lipid delivery | Alnylam, Denali |

Apolipoprotein-Targeted Companies

Eli Lilly

• Focus: APOE4 function correctors
• Lead Candidate: LY3372689
• Mechanism: Small molecule that restores APOE4 lipidation and function to APOE3-like state; improves amyloid clearance and reduces neurotoxicity
• Indication: Alzheimer's disease (APOE4 carriers)
• Stage: Phase 1
• Notes: First-in-class APOE4 modulator addressing the underlying dysfunction caused by the risk allele. Addresses both amyloid and tau pathology through restored APOE function[@apoe_ad]
• Key Targets: APOE4 lipidation, amyloid-beta clearance, synaptic function

Lexeo Therapeutics

• Focus: APOE gene therapy for APOE4 homozygotes
• Lead Candidate: LX1001 (APOE2 delivery)
• Mechanism: AAV-delivered APOE2 gene to replace APOE4 with protective APOE2 allele; APOE2 carriers have dramatically reduced AD risk
• Indication: Alzheimer's disease (APOE4 homozygotes)
• Stage: Phase 1/2
• Notes: Founded based on research showing APOE2 carriers have 90% reduced AD risk. Initial data showed dose-dependent APOE2 expression in CSF and potential reduction of amyloid plaques. Also developing APOE4-directed programs
• Clinical Trials: LX1001 Phase 1/2 study in APOE4/4 homozygotes
• Key Targets: APOE2 expression, amyloid plaque reduction, neuroprotection

Denali Therapeutics

• Focus: ABCA1 modulators and LRP1 transport vehicle platform
• Lead Candidate: DNL593 (PTV-ABCA1)
• Mechanism: ABCA1 modulator to enhance APOE lipidation; LRP1 transport vehicle enables BBB crossing and brain delivery of therapeutic proteins
• Indication: Alzheimer's disease
• Stage: Preclinical/Phase 1
• Notes: Strong academic foundations from Stanford collaboration on ABCA1 and brain cholesterol transport. Transport vehicle platform enables broader CNS therapeutics
• Key Targets: ABCA1, LRP1, APOE lipidation, amyloid clearance

Lipid Transport Modulator Companies

AC Immune

• Focus: APOE-targeted antibodies and small molecules
• Lead Candidate: ACI-35 (phospho-tau vaccine), small molecule APOE modulators
• Mechanism: Anti-APOE4 antibodies to neutralize toxic APOE4 fragments; small molecules to correct APOE4 misfolding
• Indication: Alzheimer's disease
• Stage: Preclinical/Phase 1
• Notes: Partnership with Lilly on APOE-related programs. Strong pipeline targeting various AD mechanisms
• Key Targets: APOE4, phospho-tau, amyloid

Acer Therapeutics

• Focus: ABCA1 modulator for neurodegenerative diseases
• Mechanism: ABCA1 expression enhancer to improve brain lipid transport and APOE lipidation
• Indication: Alzheimer's disease, ABCA1 deficiency-related conditions
• Stage: Research
• Notes: Focused on rare diseases with ABCA1 deficiency but exploring broader AD applications
• Key Targets: ABCA1 expression, lipid transport

Cerenis Therapeutics

• Focus: HDL mimetics and lipid transport enhancers
• Lead Candidate: CER-001 (HDL mimetic)
• Mechanism: Synthetic HDL-like particles to enhance reverse cholesterol transport and brain lipid homeostasis
• Indication: Alzheimer's disease, atherosclerosis
• Stage: Phase 2 (CVD), preclinical (AD)
• Notes: Originally developed for cardiovascular indications; brain applications leverage HDL's role in neuronal lipid homeostasis
• Key Targets: HDL function, cholesterol efflux, brain lipid transport

Research and Academic Programs

University of Washington / Mayo Clinic / UCI Programs

• Focus: APOE biology and lipid transport in AD
• Mechanism: Understanding ABCA1/ABCG1 regulation of brain cholesterol and APOE lipidation; developing gene therapy approaches
• Notes: Major academic centers driving basic science understanding of APOE and lipid transport in neurodegeneration

Pipeline Overview

| Company | Candidate | Mechanism | Stage | Indication |
|---------|-----------|-----------|-------|------------|
| Eli Lilly | LY3372689 | APOE4 corrector | Phase 1 | AD (APOE4+) |
| Lexeo | LX1001 | APOE2 gene therapy | Phase 1/2 | AD (APOE4/4) |
| Denali | DNL593 | ABCA1 modulator | Preclinical | AD |
| AC Immune | APOE modulators | APOE4 corrector | Preclinical | AD |
| Cerenis | CER-001 | HDL mimetic | Preclinical | AD |

Scientific Rationale

The APOE gene encodes apolipoprotein E, a protein essential for lipid transport in the brain. APOE4, the strongest genetic risk factor for late-onset AD, leads to:

• Reduced APOE protein secretion and impaired lipidation
• Enhanced amyloid-beta aggregation and reduced clearance
• Increased tau phosphorylation and neurofibrillary tangle formation
• Impaired synaptic plasticity and neuronal resilience
• Dysregulated cholesterol homeostasis in neurons and glia

Restoring proper lipid transport through APOE modulation, ABCA1/ABCG1 enhancement, or HDL function represents a disease-modifying approach targeting a fundamental upstream pathological mechanism in AD.

References